| [1] |
Minig L, Patrono MG, Romero N, et al. Different strategies of treatment for uterine cervical carcinoma stage ⅠB2-ⅡB[J]. World J Clin Oncol, 2014, 5(2): 86-92.
|
| [2] |
李霓,郑荣寿,张思维,等. 2003－2007年中国宫颈癌发病与死亡分析[J]. 中国肿瘤,2012, 21(11): 801-804.
|
| [3] |
邢艳,吴玉梅. 紫杉醇联合铂类新辅助化疗治疗局部晚期宫颈癌的临床研究[J]. 中国医药导报,2015, 12(29): 17-22.
|
| [4] |
Frei E3rd. Clinical cancer research: an embattled species[J]. Cancer, 1982, 50(10): 1979-1992.
|
| [5] |
Banzai C, Yahata T, Tanaka K. Trends in the incidence of uterine cancer in Niigata, Japan: a population-based study from 1982 to 2007[J]. Eur J Gynaecol Oncol, 2011, 32(5): 521-524.
|
| [6] |
Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a Meta-analysis[J]. J Cancer Res Clin Oncol, 2013, 139(11): 1887-1898.
|
| [7] |
卢红,陈娟,余丹绯,等. 伊立替康联合顺铂新辅助化疗治疗局部晚期宫颈癌的临床研究[J]. 河北医药,2016, 38(5)：700-702.
|
| [8] |
Bader AA, Petru E, Winter R. Long-term follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancy[J]. Gynecol Oncol, 2007, 105(1): 269-272.
|
| [9] |
王丹青,李清丽,李克敏,等. 新辅助化疗延期治疗妊娠期宫颈癌1例报告[J]．中国实用妇科与产科杂志,2016, 32(3)：284-285.
|
| [10] |
Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines[J]. Med Pediatr Oncol, 2001, 37(1): 1-3.
|
| [11] |
Gong L, Lou JY, Wang P, et al. Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage ⅠB2-ⅡB cervical cancer[J]. Int J Gynaecol Obstet, 2012, 117(1): 23-26.
|
| [12] |
赵群,邢艳,耿宇宁,等. 局部晚期宫颈癌新辅助化疗后临床病理分析[J]. 北京医学,2015, 37(7): 637-640.
|
| [13] |
崔云静,张申华,杨艳华,等. 新辅助化疗治疗宫颈癌患者临床疗效观察及对患者生存质量的影响[J]. 山西医药杂志,2016, 45(6): 723-726.
|
| [14] |
Gong L, Zhang JW, Yin RT, et al. Safety and efficacy of neoadjuvant chemotherapy followed by radical surgery versus radical surgery alone in locally advanced cervical cancer patients[J]. Int J Gynecol Cancer, 2016, 26(4): 722-728.
|
| [15] |
Lèguevaque P, Motton S, Delannes M, et al. Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer？[J]. Eur J Obstet Gynecol Reprod Biol, 2011, 155(2): 188-192.
|
| [16] |
Qin T, Zhen J, Zhou M, et al. Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage Ⅱ cervical squamous cell carcinoma: a retrospective cohort study[J]. Int J Surg, 2016, 30: 121-125.
|
| [17] |
Behtash N, Nazari Z, Ayatollahi H, et al. Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage ⅠB-ⅡA cervical cancer[J]. Eur J Surg Oncol, 2006, 32(10): 1226-1230.
|
| [18] |
Kim K, Kim MJ, Chung HH, et al. Inadvertent potential risk of neoadjuvant chemotherapy in cervical cancer[J]. Med Hypotheses, 2009, 73(6): 1005-1007.
|
| [19] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer(version 1.2016)[EB/OL]. (2015-11-30)[2016-11-02].
URL
|
| [20] |
Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage ⅠB1 to ⅡA cervical cancer: an international collaborative Meta-analysis[J]. Eur J Surg Oncol, 2013, 39(2): 115-124.
|
| [21] |
Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase Ⅲ randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages ⅠB2,ⅡA2,and ⅡB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)[J]. Br J Cancer, 2013, 108(10): 1957-1963.
|
| [22] |
Bermudez A, Bhatla N, Leung E. Cancer of the cervix uteri[J]. Int J Gynaecol Obstet, 2015, 131 Suppl 2: S88-S95.
|